Acta Med. 2002, 45: 33-37

https://doi.org/10.14712/18059694.2019.54

Triglycerides Predict Plasma Fibronectin in Children with Type I Diabetes Mellitus Rather than Diabetes

Ayşe Binnur Erbağcıa, Mehmet Tarakçıoğlua, Ahmet Erbağcıb, Mehmet Gözübüyükc, Necat Yılmaza, Rukiye Devecia, Ramazan Kocabaşa

aUniversity of Gaziantep, School of Medicine, Department of Biochemistry and Clinical Biochemistry, Turkey
bUniversity of Gaziantep, School of Medicine, Department of Urology, Turkey
cUniversity of Gaziantep, School of Medicine, Department of Pediatrics, Turkey

Received October 1, 2001
Accepted December 1, 2001

References

1. Cucuianu M, Bodizs G, Duncea I, Colhon D. Plasma fibronectin in overweight men and women: correlation with serum triglyceride levels and serum cholinesterase activity. Blood Coagul Fibrinolysis 1996; 7(8):779–85. <https://doi.org/10.1097/00001721-199611000-00006>
2. Doxey DL, Nares S, Park B, Trieu C, Cutler CW, Iacopino AM. Diabetes- induced impairment of macrophage cytokine release in a rat model: potential role of serum lipids. Life Sciences 1998; 13:1127–36. <https://doi.org/10.1016/S0024-3205(98)00374-9>
3. Erem C, Değer O, Bostan M et al. Plasma lipoprotein (a) levels in Turkish NIDDM patients with and without vascular diabetic complications. Acta Cardiol 1999; 54:203–7.
4. Gershon D, Roth R. Studies of the nature of faulty protein molecules and their diminished degradation in cells of aging organisms: functional implications. In: Bergener M, Ermini M, Stahelin HB (eds.) The 1998 Sandoz lectures in gerontology ‘Crossroads in aging’ New York: Academic Press 1998:25–33.
5. Hynes RO. Fibronectins. Sci Am 1986; 254:4251. <https://doi.org/10.1038/scientificamerican0686-42>
6. Hynes RO. Molecular biology of fibronectin. Ann Rev Cell Bid 1985; 1:67–90. <https://doi.org/10.1146/annurev.cb.01.110185.000435>
7. Jialal I. Envolving lipoprotein risk factors: lipoprotein(a) and oxidized low density lipoprotein. Clin Chem 1998; 44(8B):1827–1832.
8. Kanters SDJM, Jan-Dirk B, Ale A, Frjins, RCJM, Beutler JJ, Rob F. Plasma levels of cellular fibronectin in diabetes mellitus. Diabetes Care 2001; 24(2):323. <https://doi.org/10.2337/diacare.24.2.323>
9. Klaya F, Durlach V, Bertin E, Monier F, Monboisse JC, Gillery P. Evaluation of serum glycated lipoprotein (a) levels in noninsülin-dependent diabetic patients. Clin Biochem 1997; 30:227–30. <https://doi.org/10.1016/S0009-9120(97)00026-X>
10. Labat-Robert J, Marques MA, N’Doye S, et al. Plasma fibronectin in French centenarians. Arch Gerontol Geriatr 2000; 95–105. <https://doi.org/10.1016/S0167-4943(00)00071-6>
11. Olsson U, Bondjers G, Camejo G. Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes 1999; 48(3):616–22. <https://doi.org/10.2337/diabetes.48.3.616>
12. Peters JH, Sporn LA, Ginsberg MH, Wagner DD. Human endothelial cells synthesize, process, and secrete fibronectin molecules bearing an alternatively spliced type II homology (ED1). Blood 1990; 75:1801–8.
13. Peters JH, Maunder RJ, Woolf AD, Cochrane CG, Ginsberg MH. Elevated plasma levels of ED1+(cellular) fibronectin in patients with vascular injury. J Lab Clin Med 1989; 11(3):586–97.
14. Rifai N, Bachorik PS, Albers JJ. Lipids, Lipoproteins and Apolipoproteins. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry. Philadelphia: WB Saunders, 1999:809–62.
15. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry. Philadelphia: WB Saunders, 1999:750–809.
16. Shermann LA, Lee J. Fibronectin: blood turnover in normal animals and during intravascular coagulation. Blood 1982; 60:558–63.
17. Shi H, Fang J, Yang X, Shen Z, Zhu X. Lipoprotein(a) concentration and apolipoprotein( a) phenotype in subjects with type II diabetes mellitus. Chin Med J 1998; 111:1013–30.
18. Simo R, Segura RM, Garcia-Pascual L et al. Fibronectin and diabetes mellitus : the factors that influence its plasma concentrations and its usefulness as a marker of late complications. Med Clin (Barc) 1999; 112(2):45–50.
19. Song KS, Kim HK, Shim W, Jee SH. Plasma fibronectin levels in ischemic heart disease. Atherosclerosis 2001; 154(2):449–53. <https://doi.org/10.1016/S0021-9150(00)00490-1>
20. Sönmez H, Suer S, Kökoğlu E, et al. The importance of Lp(a) fibronectin interaction in atherogenesis. Haematologia (Budap) 1997; 28(3):149–53.
21. Sud SS, Gupta I, Dhaliwal LK, Kaur B, Ganguly NK. Serial plasma fibronectin levels in pre-eclamptic and normotensive women. Int J Gynecol Obstet 1999; 66:123–8. <https://doi.org/10.1016/S0020-7292(99)00072-7>
22. Testa R, Bonfigli AR, Sirplla C, et al. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type I levels in Type II diabetic patients without complications. Diabetes Nutr Metab 2000; 13(5):269–75.
23. Yamada K, Kennedy DW. Fibroblast cellular and plasma fibronectin are similar but not identical. J Cell Bid 1979; 80:492–8. <https://doi.org/10.1083/jcb.80.2.492> <PubMed>
24. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19(4):972–8. <https://doi.org/10.1161/01.ATV.19.4.972>
25. Zozulinska D, Derc K, Majchrzak A, Szczepanik A, Wierusz-Wysocka B. Assesment of plasma fibronectin concentration in type I diabetic patients. Pol Arch Med Wewn 1999; 102(3):773–7.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive